The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost–utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up

Abstract

on behalf of the UK ABLE trial investigatorsThe Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 09/144/51. The contractual start date was in September 2011. The draft report began editorial review in September 2016 and was accepted for publication in April 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the int...

Long-Term Survival and Quality of Life in Non-Surgical Adult Patients Supported with Veno-Arterial Extracorporeal Oxygenation

“…Some patients refused to participate in the study, and some were lost to follow-up. However, our loss to follow-up and dropout rates was comparable to those of other published studies [ 16 , 21 ]. The use of the EQ-5D-5L questionnaire is another limitation.…”

“…The EQ-5D-5L is a standardized measure developed by the EuroQol group to provide a simple, generic measure of health for clinical and economic appraisal [ 20 ]. It has been well-validated in several studies for critical care populations ([ 21 , 22 ]) but has only been used once in an ECMO population [ 23 ]. We are not aware of any studies that have validated EQ-5D in ECMO populations.…”

The oxygen saturation of red blood cell concentrates: The basis for a novel index of red cell oxidative stress

“…Single‐center retrospective studies examining the sequelae of transfusion of older stored blood to trauma and acutely bleeding patients have indicated an increase in patient morbidity and even mortality 6‐8,21‐27 with older age of blood. However, numerous well‐designed and executed multicenter clinical studies that have been undertaken to examine the clinical consequences of transfusing RBCs with accumulated storage lesion by comparing “fresher” versus “standard practice” RCC found no clear differences in mortality 28,29 or major morbidities 30,31 . All these studies used storage time as the surrogate for loss of quality by storage lesion accumulation, assuming that all prepared RCCs are equivalent and accumulate lesions at the same rate.…”

Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical risk

“…Costs considered in the analysis are direct health care costs, encompassing both in-hospital and long-term costs ( Table 1 ), in order to adopt a comprehensive third-party payer cost perspective. The in-hospital costs related to hospitalization for an AVR include operating room (both personnel and materials, excluding cost for the devices), 7 , 9 , 13 , 37 – 39 preoperative/intraoperative/postoperative diagnostic exams, 13 , 40 – 44 device costs, 7 , 45 , 46 reoperation for reexploration or second valve implantation, 47 – 49 hospital stay with or without mechanical ventilation, 50 – 56 blood transfusion, 37 , 50 , 51 , 57 , 58 need for renal replacement therapy, 50 , 51 , 57 , 59 and adverse events, such as stroke 49 , 54 , 60 – 62 or PMI. 37 , 38 , 48 , 49 , 54 , 63 According to the lifetime horizon of the simulation, patients who developed chronic renal dysfunction receive dialysis until death.…”